DEF: My Size, Inc. Seeks Shareholder Approval for Director Elections and Significant Equity Plan Expansion
Proxy Statement
My Size, Inc. has issued its definitive proxy statement for its Annual Meeting on September 4, 2025, seeking shareholder approval for the re-election of two Class I directors, a substantial increase in its 2017 Equity Incentive Plan share reserve, and the adoption of an evergreen provision for future equity awards.
Summary
- An Annual Meeting of Stockholders will be held on September 4, 2025, at 10:00 a.m. local time in Tel Aviv, Israel.
- Shareholders will vote on the election of Arik Kaufman and Roy Golan as Class I directors for a three-year term.
- A proposal seeks to amend the My Size, Inc. 2017 Equity Incentive Plan to increase the common stock reservation for issuance from 130,000 shares to 756,691 shares.
- Another proposal aims to adopt an evergreen provision for the 2017 Plan, automatically increasing the share reserve annually from January 1, 2026, to January 1, 2029, by the lesser of 5% of outstanding common stock or a board-determined smaller number.
- Shareholders will also vote to ratify the appointment of Somekh Chaikin as the independent public accountant for the fiscal year ending December 31, 2025.
- The board of directors unanimously recommends a vote FOR all four proposals.
- As of July 8, 2025, there were 3,103,076 shares of the company's common stock issued and outstanding.
- Net loss decreased from $6,380,000 in fiscal year 2023 to $3,995,000 in fiscal year 2024.
- The cumulative total shareholder return (TSR) for a $100 investment made on December 31, 2022, was $199 at December 31, 2023, and decreased to $157 at December 31, 2024.
Sentiment
Score: 6
Explanation: The document is primarily a proxy statement for routine corporate governance matters and equity plan adjustments. The significant reduction in net loss is a positive financial indicator, suggesting improved operational efficiency. However, the negative trend in Total Shareholder Return (TSR) and the potential for dilution from the evergreen equity plan temper the overall sentiment. The proposals are generally aimed at long-term talent retention and operational continuity.
Positives
- The company's net loss significantly decreased from $6,380,000 in fiscal year 2023 to $3,995,000 in fiscal year 2024, indicating improved financial performance.
- The proposed increase in the 2017 Equity Incentive Plan share reserve and the adoption of an evergreen provision are intended to attract and retain key personnel, which is crucial for long-term growth and success in a competitive labor market.
- The board of directors recommends approval of all proposals, signaling confidence in the strategic direction and governance measures.
- The company has implemented robust corporate governance policies, including a Code of Business Conduct and Ethics, an Insider Trading Policy, and an Executive Officer Clawback Policy, enhancing accountability and compliance.
Negatives
- The cumulative total shareholder return (TSR) for a $100 investment on December 31, 2022, decreased from $199 at December 31, 2023, to $157 at December 31, 2024, indicating a decline in shareholder value over the most recent period.
- Compensation actually paid to the Principal Executive Officer (PEO) decreased from $537,307 in fiscal 2023 to $526,822 in fiscal 2024.
- Average compensation actually paid to Non-PEO Named Executive Officers (NEOs) decreased from $377,448 in fiscal 2023 to $337,816 in fiscal 2024.
Risks
- There is an insufficient number of shares remaining under the current 2017 Equity Incentive Plan to meet projected needs, which could impair the company's ability to attract and retain key personnel if the proposed amendments are not approved by stockholders.
- The evergreen provision for the 2017 Plan, if approved, has no explicit limit on the total number of shares that may become available for issuance, potentially leading to significant future dilution for existing shareholders.
- The enforceability of non-competition provisions in executive employment agreements may be limited under applicable law, which could impact the company's ability to protect its interests if executives depart.
Future Outlook
The company expects the proposed Evergreen Provision under the 2017 Plan to provide enough shares for awards for approximately four years, assuming current granting practices and historical usage, maximum annual evergreen increases, and further dependent on the future price of shares and hiring activity. However, the company cannot predict future equity grant practices, share prices, or hiring activity with certainty, and the share reserve could last for a shorter or longer time.
Management Comments
- "Because of the significance of these proposals to the Company and its stockholders, it is vital that every stockholder votes at the Annual Meeting in person or by proxy."
- "We believe that operation of the 2017 Plan is a necessary and powerful tool in attracting and retaining the services of key employees, key contractors, and outside directors in a competitive labor market, which is essential to our long-term growth and success."
- "We also need to ensure that we can continue to provide an incentive to our current employees, contractors and outside directors, many of whom hold outstanding options that were previously awarded under the 2017 Plan with exercise prices above the current fair market value of our common stock."
- "We strongly believe that evergreen proposal is essential to our continued success and therefore is in the best interests of the Company and our stockholders, since it allows us to annually maintain a sufficient number of shares of common stock issuable under the 2017 Plan, which is necessary for us to be able to provide our employees with sufficient award grants under the 2017 Plan to incentivize them to work with the Company and to maintain their services."
Industry Context
The document highlights the company's need to attract and retain key talent in a competitive labor market, a common challenge in the technology sector. The reliance on equity incentive plans, including a proposed evergreen provision, aligns with industry practices to incentivize employees and align their interests with long-term company performance. The company's operations in retail technology and AI deployment, particularly through its subsidiary Naiz Fit, position it within a dynamic and evolving market segment where innovation and skilled personnel are critical for success.
Comparison to Industry Standards
- The company's classified board structure with staggered three-year terms is a common corporate governance practice, though some institutional investors and governance advocates prefer annual elections for all directors to enhance accountability.
- The proposed increase in the 2017 Equity Incentive Plan share reserve to 756,691 shares and the adoption of a 5% evergreen provision are significant. While equity compensation is standard in the technology industry to attract and retain talent, the potential for ongoing dilution from an uncapped evergreen provision warrants careful consideration compared to plans with more defined limits.
- The reduction in net loss from $6.38 million in 2023 to $3.995 million in 2024 indicates an improvement in financial efficiency, which should be benchmarked against the profitability trends of comparable companies in the retail technology or AI solutions space.
- The decline in Total Shareholder Return (TSR) from $199 to $157 (based on a $100 initial investment from December 31, 2022) suggests underperformance relative to a hypothetical benchmark, necessitating a detailed comparison against relevant industry indices or direct competitors' stock performance over the same period.
- The executive compensation structure, including base salary, bonus, stock awards, and option awards, is consistent with typical practices in publicly traded technology companies. The inclusion of 'Managers Insurance' and 'Education Fund' as social benefits reflects customary employment practices in Israel, where the company is based.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Or Kles | Oren Elmaliah | 2025-04-01 | Mr. Kles resigned as CFO effective March 31, 2025, and Mr. Elmaliah was appointed as his successor. |
| Chief Growth Officer | NA | Borja Cembrero Saralegui | 2025-05-01 | Appointment to a new executive role within the company. |
| Director | Oren Elmaliah | NA | 2025-03-06 | Stepped down from the board of directors and all committees in connection with his appointment as Chief Financial Officer. |
| Director | NA | Roy Golan | 2025-03-25 | Appointed as a new member of the board of directors. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Structure | The board of directors is classified into three classes with staggered three-year terms. Class I directors (Arik Kaufman, Roy Golan) are up for re-election, with their terms expiring at the Annual Meeting. Class II (Oron Branitzky, Guy Zimmerman) terms expire at the 2026 annual meeting, and Class III (Ronen Luzon) term expires at the 2027 annual meeting. | NA | This classified structure provides board continuity and stability but may limit immediate shareholder influence over board composition compared to annually elected boards. |
| Equity Incentive Plan Amendment | Proposed amendment to the 2017 Equity Incentive Plan to increase the common stock reserved for issuance from 130,000 shares to 756,691 shares. | Upon stockholder approval | Aims to enhance the company's ability to attract and retain key personnel by providing sufficient equity incentives, but will result in potential dilution for existing shareholders. |
| Equity Incentive Plan Evergreen Provision | Proposed amendment to the 2017 Plan to adopt an evergreen provision, automatically increasing the share reserve annually from January 1, 2026, to January 1, 2029, by the lesser of 5% of outstanding common stock or a board-determined smaller number. | Upon stockholder approval, effective January 1, 2026 | Ensures a continuous supply of shares for future awards to incentivize employees, but introduces ongoing potential for dilution without a fixed cap on the total shares available through this mechanism. |
| Audit Committee Composition | The audit committee is comprised of Oron Branitzky, Roy Golan, and Arik Kaufman, with Roy Golan serving as chairman. All members are determined to be independent by applicable SEC and Nasdaq Market rules. Oren Elmaliah is identified as an audit committee financial expert. | NA | Ensures independent oversight of financial reporting, internal controls, and auditor relations, which enhances investor confidence and financial integrity. |
| Compensation Committee Composition | The compensation committee consists of Oron Branitzky, Roy Golan, and Arik Kaufman, with Oron Branitzky serving as chairman. All members are determined to be independent by Nasdaq Market rules. | NA | Provides independent oversight of executive compensation programs, aiming to align executive incentives with company performance and shareholder interests. |
| Nominating and Governance Committee Composition | The nominating and corporate governance committee members are Oron Branitzky, Roy Golan, and Arik Kaufman, with Arik Kaufman serving as chairman. All members are determined to be independent by Nasdaq Market rules. | NA | Responsible for developing corporate governance principles and considering director nominees, promoting sound governance practices and board diversity. |
| Policy Adoption | The company has adopted a Code of Business Conduct and Ethics, an Insider Trading Policy (prohibiting short sales, options, and hedging transactions), and an Executive Officer Clawback Policy (requiring recoupment of erroneously awarded compensation upon accounting restatement). | NA | These policies enhance ethical conduct, promote compliance with securities laws, and strengthen accountability for executive compensation, aligning with best practices in corporate governance. |
Legal Proceedings
- The company is not aware of any of its directors or officers being involved in any legal proceedings in the past ten years relating to bankruptcy, insolvency, criminal proceedings (other than traffic and other minor offenses), or being subject to any of the items set forth under Item 401(f) of Regulation S-K.
Related Party Transactions
- Ronen Luzon (Chief Executive Officer and Director) and Billy Pardo (Chief Operating Officer and Chief Product Officer) are husband and wife.
- The company has entered into written employment agreements with each of its executive officers, including Ronen Luzon and Billy Pardo, detailing their compensation and benefits.
- Options and restricted stock awards have been granted to officers and directors since the company's inception, which may contain acceleration provisions upon certain merger, acquisition, or change of control transactions.
- An agreement was entered into with Accounting Team Ltd., an entity 100% owned by Oren Elmaliah (Chief Financial Officer), for bookkeeping, controller, and CFO services, with a monthly fee of NIS 63,000 (approximately $18,000).
Stakeholder Impact
- **Shareholders**: Will be directly impacted by the outcome of the votes on director elections and the significant expansion of the equity incentive plan, which could lead to potential dilution of existing shareholdings. The decline in TSR indicates a negative impact on shareholder value in the recent period.
- **Employees/Executives**: Directly benefit from the equity incentive plan, which provides compensation and incentives for their performance and retention. Management changes affect specific individuals and their roles within the company. The clawback policy introduces a layer of accountability for executive compensation.
- **Customers/Suppliers**: While not directly addressed, the company's ability to attract and retain key talent through its equity plans could indirectly influence its capacity for innovation, product development, and service delivery, potentially impacting customer satisfaction and supplier relationships.
- **Creditors**: Not explicitly mentioned, but the reported reduction in net loss could indirectly signal improved financial health, potentially enhancing the company's creditworthiness.
Next Steps
- Stockholders are urged to vote on the proposals at the Annual Meeting on September 4, 2025, either in person or by proxy.
- The company intends to begin sending the Notice of Internet Availability of Proxy Materials to stockholders on or about July 11, 2025.
- Stockholders will receive instructions on how to access proxy materials online or request paper copies.
- If stockholders do not approve the selection of Somekh Chaikin as the independent registered accounting firm, the audit committee will reconsider the appointment.
- Stockholder proposals for inclusion in the 2026 annual meeting proxy materials must be received by the corporate secretary on or before March 11, 2026.
- Director nominations or other business proposals for the 2026 Annual Meeting (not included in proxy materials) must be submitted between May 7, 2026, and June 6, 2026.
- The evergreen provision for the 2017 Plan, if approved, will automatically increase the share reserve annually from January 1, 2026, to January 1, 2029.
Key Dates
| Date | Description |
|---|---|
| 2022-12-08 | Effective date of 1-for-25 reverse stock split. |
| 2022-12-31 | Per share closing price of common stock was $2.72. |
| 2023-01-01 | Start of fiscal year 2023. |
| 2023-07-13 | Compensation committee reduced exercise price of outstanding options to $8.72 per share. |
| 2023-10-01 | Roy Golan's previous company, Ayala Pharmaceuticals, Inc., merged with BioSight Ltd. |
| 2023-12-27 | Stockholders voted to increase 2017 Plan reservation to 130,000 shares. |
| 2023-12-31 | End of fiscal year 2023; per share closing price of common stock was $5.40; Net Loss of $6,380,000. |
| 2024-01-01 | Start of fiscal year 2024. |
| 2024-02-14 | Grant date for 37,500 restricted shares to Ronen Luzon and 18,750 restricted shares to Or Kles and Billy Pardo. |
| 2024-04-19 | Effective date of 1-for-8 reverse stock split. |
| 2024-06-01 | Roy Golan began serving as a financial advisor. |
| 2024-07-01 | Ronen Luzon's monthly base salary increased to NIS 60,500. |
| 2024-07-01 | Roy Golan began serving as a director of Neurosense Therapeutics Ltd. |
| 2024-11-01 | Guy Zimmerman began serving as Chief Executive Officer of XJet 3D. |
| 2024-12-31 | End of fiscal year 2024; per share closing price of common stock was $4.27; Net Loss of $3,995,000. |
| 2025-03-01 | Effective date of agreement with Accounting Team Ltd. for CFO services. |
| 2025-03-06 | Oren Elmaliah stepped down as a member of the board of directors. |
| 2025-03-25 | Roy Golan began serving as a member of the board of directors. |
| 2025-03-27 | 2024 Annual Report on Form 10-K filed with the SEC. |
| 2025-03-31 | Or Kles resigned as Chief Financial Officer. |
| 2025-04-01 | Oren Elmaliah appointed as Chief Financial Officer. |
| 2025-05-01 | Borja Cembrero Saralegui began serving as Chief Growth Officer. |
| 2025-06-04 | Compensation committee reduced exercise price of outstanding options to $1.28 per share; compensation committee recommended increasing 2017 Plan shares to 756,691. |
| 2025-07-08 | Record Date for Annual Meeting, determining stockholders entitled to vote. |
| 2025-07-09 | Date of Notice of Annual Meeting and Proxy Statement. |
| 2025-07-11 | Intended date to begin sending Notice of Internet Availability of Proxy Materials. |
| 2025-09-04 | Date of Annual Meeting of Stockholders. |
| 2026-01-01 | Start date for Evergreen Provision for 2017 Plan, automatically increasing share reserve. |
| 2026-03-11 | Deadline for stockholder proposals for 2026 Annual Meeting to be included in proxy materials. |
| 2026-05-07 | Earliest date for submission of director nominations or other business proposals for 2026 Annual Meeting not included in proxy statement. |
| 2026-06-06 | Latest date for submission of director nominations or other business proposals for 2026 Annual Meeting not included in proxy statement. |
| 2026-07-06 | Latest date for stockholders to provide notice for soliciting proxies for director nominees other than company nominees for 2026 Annual Meeting. |
| 2029-01-01 | End date for Evergreen Provision for 2017 Plan. |
Keywords
Proxy Statement, Annual Meeting, Equity Incentive Plan, Stock Options, Corporate Governance, Director Election, Shareholder Approval, Executive Compensation, SEC Filing, My Size Inc, Nasdaq, Financial Reporting, Risk Management, Strategic Business Analysis, Share Dilution, Net Loss
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.